- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07304154
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment (HERMOSA-2)
A Phase 1, Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.
The primary objectives of this study are:
- To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases
- To determine the recommended dose for Phase 1b
- To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Medical Information
- Telefonnummer: 844-454-5483(1-844-454-KITE)
- E-Mail: medinfo@kitepharma.com
Studienorte
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2139
- Rekrutierung
- Concord Repatriation General Hospital
-
Westmead, New South Wales, Australien, 2145
- Rekrutierung
- Corner Hawkesbury Road and Darcy Road
-
-
-
-
-
Montreal, Kanada, H3T 1E2
- Rekrutierung
- Jewish General Hospital
-
Montreal, Kanada, H1T 2M4
- Rekrutierung
- Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont
-
Ottawa, Kanada, K1H 8L6
- Rekrutierung
- The Ottawa Hospital - General Campus
-
-
-
-
California
-
Newport Beach, California, Vereinigte Staaten, 92663
- Rekrutierung
- Hoag Memorial Hospital Presbyterian
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- Stanford Neuroscience Health Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Irving Medical Center
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84143
- Rekrutierung
- LDS Hospital - Intermountain Health
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- Fred Hutchinson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
-
Age 18 through 65 for relapsing forms of MS, 18 through 75 for progressive forms of MS, above 18 years of age for MG and CIDP.
-
Reproductive status-related eligibility and contraception requirements:
- Individuals must agree to use protocol-specified method(s) of contraception where applicable
Inclusion Criteria for multiple sclerosis (MS):
MS (Relapsing and progressive forms):
- Diagnosed with MS according to the 2017 revision of the McDonald diagnostic criteria
Relapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):
- Inadequate response to previous therapies is defined as evidence of breakthrough disease activity within 12 months prior to screening while on high efficacy disease-modifying therapy (DMT) OR Inadequate response to previous therapies defined as intolerance to ≥ 2 DMTs due to side effects prohibiting the chronic use of the DMT.
- Expanded Disability Status Scale (EDSS) 0 to 6.0
Progressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):
- Inadequate response to previous therapies is defined as evidence of disease progression within 12 months prior to screening despite standard of care therapy for naSPMS or despite ocrelizumab, where available, for PPMS
- Absence of clinical relapses for at least 24 months
- No evidence of Gadolinium enhancing (GadE+) on magnetic resonance imaging (MRI) brain at screening or baseline
- EDSS of 3 to 6.5 who are ambulatory
Inclusion Criteria for myasthenia gravis (MG):
- Documentation of autoantibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or low-density lipoprotein receptor-related protein 4 (LRP4)
- Diagnosis of MG with generalized weakness meeting criteria as defined by the Myasthenia Gravis Foundation of American (MGFA) classification of II- IV at screening
- Myasthenia Gravis Activities of Daily Living (MG-ADL) score ≥ 6 (> 50% of the total score due to non-ocular symptoms)
- Quantitative Myasthenia Gravis (QMG) score ≥ 10
- Inadequate response to previous therapies while taking at least 2 classes of immunosuppressants (ie, steroids, azathioprine (AZA), mycophenolate mofetil (MMF), intravenous immunoglobulin (IVIg), biologics (eg, rituximab, anti-FcRN class, and anti-complement class))
- Thymectomy allowed if completed ≥ 12 months prior to screening
Inclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):
-
Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria
- For the Phase 1b CIDP cohort, diagnosis will be confirmed by independent adjudication once the adjudication committee is established and operational
-
CIDP Disease Activity Status (CDAS) score ≥ 3 at screening and confirmed at the final pre treatment assessment prior to infusion
-
Inflammatory neuropathy cause and treatment (INCAT) score ≥ 3 at screening and confirmed at one of more protocol-defined baseline assessments during the Extended Screening Period with Observational Run-in; individuals must also continue to meet clinical eligibility criteria at the final pre-treatment assessment prior to infusion
-
Inadequate response to previous therapies despite adequate trial of standard of care therapy (≥ 8-12 weeks at standard dosing with stable regimen of either steroids, IVIg, SCIg, plasmapheresis exchange (PLEX), rituximab or anti-FcRN) and either failure, intolerance, or contraindication to at least one additional standard therapy (ie, steroids, IVIg, subcutaneous immunoglobulin (SCIg), plasmapheresis exchange (PLEX), rituximab, or anti FcRN), unless medically inappropriate OR Unable to tolerate standard of care resulting in discontinuation due to side effects, with ongoing disease activity
-
Except for nodal/paranodal CIDP, historical documentation of objective improvement in the past 24 months while on IVIg, SCIg, PLEX, or anti-FcRN OR Historical documentation of objective disease worsening in the past 24 months when IVIg, SCIg, PLEX, or anti-FcRN has been reduced or interrupted
Key Exclusion Criteria:
- History or presence of central nervous system (CNS) or peripheral nervous system disorders before enrollment that may impact cognition, strength, or cause weakness
- History of autologous or allogeneic stem cell transplant and/or organ transplant
- History of hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS)
Exclusion Criteria for MS:
- Cohort 1 or 2; inability to complete 9-hole Peg Test (9-HPT) in < 240 seconds and Timed 25 foot Walk (T25FW) < 150 seconds
- History of hypersensitivity to parenteral administration of gadolinium-based contrast agents
- Any renal condition that would preclude the administration of gadolinium (for the relapsing forms of MS and progressive forms of MS)
- Any contraindication to lumbar puncture (LP) (for the relapsing forms of MS and progressive forms of MS)
Exclusion Criteria for MG:
- Current myasthenic crisis not effectively controlled within 2 weeks before enrollment
- Thymectomy performed within 12 months of baseline
Exclusion Criteria for CIDP:
- Pure sensory CIDP and focal CIDP
- Polyneuropathy of other causes
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Phase 1a: KITE-363 (Dose Escalation) With Lymphodepleting Chemotherapy
Participants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose. |
Administered intravenously Administered intravenously A single infusion of CAR-transduced autologous T cells administered as intravenous infusion. |
|
Experimental: Phase 1a: KITE-363 (Dose Escalation) Without Lymphodepleting Chemotherapy
Participants with RMS, PMS, MG, and/or CIDP will receive infusion of KITE-363 CAR transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose. |
A single infusion of CAR-transduced autologous T cells administered as intravenous infusion. |
|
Experimental: Phase 1b: KITE-363 (Dose Expansion)
Participants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells. |
Administered intravenously Administered intravenously A single infusion of CAR-transduced autologous T cells administered as intravenous infusion. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 1a: Prozentsatz der Teilnehmer mit dosislimitierenden Toxizitäten (DLTs) nach der Infusion von KITE-363
Zeitfenster: Bis zu 28 Tage
|
Bis zu 28 Tage
|
|
|
Phase 1b: Schubförmige Formen von MS (RRMS und aSPMS): Anzahl neuer und/oder vergrößerter T2-Läsionen in der MRT in Woche 12
Zeitfenster: Woche 12
|
Woche 12
|
|
|
Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12
Zeitfenster: Week 12
|
This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS). |
Week 12
|
|
Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders
Zeitfenster: Up to 3 years
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Up to 3 years
|
|
Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Zeitfenster: Up to 3 years
|
Clinical improvement will be analyzed using adjusted inflammatory neuropathy cause and treatment (aINCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement. |
Up to 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Spiegel von T-Zellen im Blut
Zeitfenster: Bis zu 2 Jahre
|
Bis zu 2 Jahre
|
|
|
Pharmakokinetik: Spiegel von chimären Antigenrezeptor (CAR) T-Zellen im Blut
Zeitfenster: Bis zu 2 Jahren
|
Bis zu 2 Jahren
|
|
|
Pharmakodynamik-Parameter: Spiegel der B-Zellen im Blut
Zeitfenster: Bis zu 2 Jahre
|
Bis zu 2 Jahre
|
|
|
Pharmakodynamische Parameter: Spiegel krankheitsspezifischer Biomarker und Autoantikörper im Blut
Zeitfenster: Bis zu 2 Jahren
|
Bis zu 2 Jahren
|
|
|
Anteil der Teilnehmer mit Antikörpern gegen die KITE-363 CAR-T-Zellen im Blut
Zeitfenster: Bis zu 2 Jahre
|
Bis zu 2 Jahre
|
|
|
Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate
Zeitfenster: Up to 3 years
|
Proportion of participants with annual relapse. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over Time
Zeitfenster: Up to 3 years
|
EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over Time
Zeitfenster: Up to 3 years
|
The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over Time
Zeitfenster: Up to 3 years
|
The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability. |
Up to 3 years
|
|
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over Time
Zeitfenster: Up to 3 years
|
SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed. |
Up to 3 years
|
|
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRI
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Relapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDA
Zeitfenster: Up to 3 years
|
Up to 3 years
|
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over Time
Zeitfenster: Up to 3 years
|
EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments. |
Up to 3 years
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over Time
Zeitfenster: Up to 3 years
|
The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment. |
Up to 3 years
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in 9-HPT D/ND Over Time
Zeitfenster: Up to 2 years
|
The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability. |
Up to 2 years
|
|
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over Time
Zeitfenster: Up to 3 years
|
SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed. |
Up to 3 years
|
|
MG: Proportion of Participants With at Least a 2-Point or 5 Point Improvement in MG-ADL Score up to Week 24
Zeitfenster: Up to 24 weeks
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Up to 24 weeks
|
|
MG: Change From Baseline in MG-ADL Score at Week 24
Zeitfenster: Baseline, Week 24
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Baseline, Week 24
|
|
MG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)
Zeitfenster: Up to 3 years
|
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden. |
Up to 3 years
|
|
MG: Proportion of Participants With at Least a 3-point or 5-point Improvement in Medical Research Council (QMG) Score up to Week 24
Zeitfenster: Baseline, Week 24
|
The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment. |
Baseline, Week 24
|
|
MG: Change From Baseline in QMG Score to Week 24
Zeitfenster: Baseline, Week 24
|
The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment. |
Baseline, Week 24
|
|
MG: Proportion of Participants With at Least a 3-Point Improvement in MG-C Score up to Week 24
Zeitfenster: Baseline, Up to 24 weeks
|
MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment. |
Baseline, Up to 24 weeks
|
|
Change From Baseline in MG-C Scale Score at Week 24
Zeitfenster: Baseline, Week 24
|
MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment. |
Baseline, Week 24
|
|
MG: Number of Participants With Changes in Myasthenia Gravis Foundation of American Post-Intervention Status (MGFA-PIS), Including Minimal Manifestation, Complete Stable Remission, Pharmacologic Remission
Zeitfenster: Up to 3 years
|
The MGFA-PIS is a standardized classification system which categorizes outcomes into distinct states such as complete stable remission (CSR), pharmacologic remission (PR), minimal manifestations (MM), improved, unchanged, worse, and exacerbation. CSR indicates no symptoms or signs for at least one year without therapy, while MM reflects minimal weakness without functional limitation. |
Up to 3 years
|
|
CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Zeitfenster: Week 24
|
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Week 24
|
|
Proportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24
Zeitfenster: Week 24
|
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Week 24
|
|
Proportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24
Zeitfenster: Up to Week 24
|
Up to Week 24
|
|
|
Proportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Zeitfenster: Baseline, up to Week 24
|
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Baseline, up to Week 24
|
|
Proportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Zeitfenster: Baseline, up to Week 24
|
The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement. |
Baseline, up to Week 24
|
|
CIDP: Time to First aINCAT Deterioration
Zeitfenster: Up to 3 years
|
INCAT is a clinician-administered tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability and lower score would indicate clinical improvement. |
Up to 3 years
|
|
CIDP: Proportion of Participants With Evidence of Clinical Improvement
Zeitfenster: Up to week 24
|
Clinical improvement will be analyzed using inflammatory Rasch-built overall disability scale (I-RODS) scale. I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability. |
Up to week 24
|
|
CIDP: Change From Baseline Over Time in Adjusted INCAT Score
Zeitfenster: Up to 3 years
|
INCAT is a tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in 24-Item I-RODS Score
Zeitfenster: Up to 3 years
|
I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in Medical Research Council (MRC) Sum Score
Zeitfenster: Up to 3 years
|
MRC Sum Score is a measure to assess muscle strength for people with CIDP. The score ranges from 0 to 60. Higher scores indicate better muscle strength, while lower scores reflect greater weakness. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in Timed Up and Go (TUG) Score
Zeitfenster: Up to 3 years
|
TUG test is a measure of mobility, balance, and fall risk. The score is recorded in seconds; shorter times indicate better mobility, while longer times suggest impaired balance or gait. |
Up to 3 years
|
|
CIDP: Change From Baseline Over Time in Mean Grip Strength
Zeitfenster: Up to 3 years
|
Mean Grip Strength is a quantitative measure of hand and forearm muscle strength. Higher values indicate better muscle strength, while lower values reflect weakness or functional impairment. |
Up to 3 years
|
|
Proportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
Zeitfenster: Up to 3 years
|
The EQ-5D-5L is a generic measure of health status captured on the day of assessment. Two components comprise the EQ-5D-5L: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is divided into 5 levels of severity: "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems." The EQ-5D-5L VAS is a vertical VAS for recording self-rated current HRQoL, and it ranges from 0, described as "the worst health you can imagine," to 100, described as "the best health you can imagine." EQ-5D-5L will be scored according to the published administration and scoring manual. |
Up to 3 years
|
|
Proportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)
Zeitfenster: Up to 3 years
|
The CAP-PRI is a tool developed to assess the impact of chronic acquired polyneuropathy on participant's quality of life, capturing both physical and psychological symptoms from the participant's perspective. The scoring of the CAP-PRI is typically based on how participants rate their symptoms and overall health across various dimensions, such as sensory symptoms, motor function, pain, emotional well-being, and fatigue. Each dimension of the CAP-PRI is scored separately, and the results are summed up to give an overall score for the participant, with higher scores indicating greater severity or a worse quality of life. Each domain typically uses a Likert scale or similar ordinal scale, where participants rate their experience or symptoms on a scale from 0 to 5. |
Up to 3 years
|
|
Proportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)
Zeitfenster: Up to 3 years
|
The RT-FSS or FSS-7 is a refined version of the original 9-item Fatigue Severity Scale (FSS-9) designed to improve accuracy in measuring fatigue, particularly in participants with immune-mediated neuropathies. The original 7-point Likert scale was collapsed into a 4-point response category for the remaining items to fulfill strict linearity requirements. It is a linearly weighted scale, meaning its scores provide a more precise, interval-level measurement rather than just an ordinal ranking. It was specifically validated for conditions like Guillain-Barré syndrome and CIDP. This modified scale provides a more stable test-retest reliability. The scale is used to distinguish between different levels of fatigue impact on daily activities, though it may have a ceiling effect for patients with extremely severe symptoms. |
Up to 3 years
|
|
Pharmacodynamics Parameters: Levels of Cytokines and Chemokines in Blood
Zeitfenster: Up to 2 years
|
A panel of inflammatory, immuno-modulatory and effector molecules, including cytokines and chemokines, will be measured as units of concentration in serum (e.g. pg/ml) using ligand-based immunoassays such as MSD, Ella and O-link. |
Up to 2 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Kite Study Director, Kite, A Gilead Company
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Pathologische Prozesse
- Neubildungen nach Standort
- Neubildungen
- Neuromuskuläre Erkrankungen
- Chronische Erkrankung
- Krankheitsattribute
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Erkrankungen des peripheren Nervensystems
- Demyelinisierende Autoimmunerkrankungen, ZNS
- Autoimmunerkrankungen des Nervensystems
- Demyelinisierende Krankheiten
- Neurodegenerative Krankheiten
- Paraneoplastische Syndrome, Nervensystem
- Neubildungen des Nervensystems
- Paraneoplastische Syndrome
- Erkrankungen der neuromuskulären Verbindungen
- Polyneuropathien
- Polyradikuloneuropathie
- Pathologische Zustände, Anzeichen und Symptome
- Multiple Sklerose
- Myasthenia gravis
- Polyradikuloneuropathie, chronisch entzündliche Demyelinisierung
- Organische Chemikalien
- Kohlenwasserstoffe
- Phosphoramid -Senf
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Phosphoramide
- Organophosphorverbindungen
- Cyclophosphamid
- Fludarabine
Andere Studien-ID-Nummern
- KT-US-728-0204
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .